financetom
Business
financetom
/
Business
/
Correction: Algoma Central Q2 Earnings Drop
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Correction: Algoma Central Q2 Earnings Drop
Aug 2, 2024 4:42 AM

07:25 AM EDT, 08/02/2024 (MT Newswires) -- (Correcting second paragraph of the earnings stories to make it clear the net earnings are in $000s. A corrected version follows).

Algoma Central ( AGMJF ) , a provider of marine transportation services, on Friday reported lower earnings for the second quarter on lower-than-expected revenues.

Net earnings for the quarter were $17.464 million compared to net earnings of $33.144 million for the same period in 2023, reporting adjusted earnings per share of $0.44 compared to $0.79 a year earlier, and basis EPS of $0.44 versus $0.86 a year earlier.

Revenue for the quarter was $180.968 million, below the consensus forecast of $215.80 million at Capital IQ.

"Algoma encountered a challenging second quarter, but there are encouraging indications that volumes and margins will improve in the second half of the year," said CEO Gregg Ruhl said in a statement.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cabaletta Bio reports smaller-than-expected Q3 loss
Cabaletta Bio reports smaller-than-expected Q3 loss
Nov 10, 2025
Overview * Company advancing rese-cel clinical trials with promising data for autoimmune diseases * Cabaletta expects cash reserves to fund operations into the second half of 2026 Outlook * Cabaletta plans BLA submission for rese-cel in 2027 * Company expects FDA alignment on cohort designs by end of 2025 * Cabaletta anticipates enrollment in registrational cohorts in 2026 Result Drivers...
ADC Therapeutics Q3 net income beats analyst expectations
ADC Therapeutics Q3 net income beats analyst expectations
Nov 10, 2025
Overview * ADC Therapeutics ( ADCT ) Q3 net income and income from operations beat analyst expectations * Net product revenues for Q3 2025 declined due to lower sales volume * Completed $60 mln PIPE financing to expand ZYNLONTA and strengthen balance sheet Outlook * ADC Therapeutics ( ADCT ) expects LOTIS-7 data by end of 2025 * Company anticipates...
Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities
Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities
Nov 10, 2025
Acquisition deepens Revvity Signals’ presence in research informatics while furthering its ongoing expansion into development and manufacturing solutions WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. ( RVTY ) , today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end...
Retail rally running out of steam after record streak, J.P. Morgan warns
Retail rally running out of steam after record streak, J.P. Morgan warns
Nov 10, 2025
(Reuters) -Retail investors are dialing back their risky bets after the longest bullish streak in recent years, J.P. Morgan analysts wrote in a note, marking a shift in sentiment that could sap momentum in high-flying U.S. stocks. The brokerage's readout from Friday showed a drop in bullish options bets, with call volumes slipping compared to puts, after roughly 140 days...
Copyright 2023-2026 - www.financetom.com All Rights Reserved